According to the Zhitong Finance App, *ST Kehua (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the China Drug Administration. The product is: “Human Immunodeficiency Virus Antigen Antibody Quality Control Product”, which complements the company's human immunodeficiency virus antigen antibody (HIVag/Ab) test kit (chemiluminescence) for the quality control of the human immunodeficiency virus antigen antibody test project.
*ST Kehua (002022.SZ) obtained the “Human Immunodeficiency Virus Antigen Antibody Quality Control Product” medical device registration certificate
This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.